What do the Universal Test and Treat trials tell us about the path to HIV epidemic control
Diane V. Havlir,Shahin Lockman,Shahin Lockman,Helen Ayles,Joseph Larmarange,Gabriel Chamie,Tendani Gaolathe,Tendani Gaolathe,Collins Iwuji,Collins Iwuji,Sarah Fidler,Sarah Fidler,Moses R. Kamya,Sian Floyd,Janet Moore,Richard J. Hayes,Maya L. Petersen,François Dabis +17 more
TL;DR: Universal test and treat (UTT) was evaluated in four randomized population‐based trials conducted in sub‐Saharan Africa during expanded antiretroviral treatment (ART) eligibility by World Health Organization guidelines and the UNAIDS 90‐90‐90 campaign.
read more
Abstract: Author(s): Havlir, Diane; Lockman, Shahin; Ayles, Helen; Larmarange, Joseph; Chamie, Gabriel; Gaolathe, Tendani; Iwuji, Collins; Fidler, Sarah; Kamya, Moses; Floyd, Sian; Moore, Janet; Hayes, Richard; Petersen, Maya; Dabis, Francois; (Universal Test, Treat Trials) UT3 Consortium | Abstract: IntroductionAchieving HIV epidemic control globally will require new strategies to accelerate reductions in HIV incidence and mortality. Universal test and treat (UTT) was evaluated in four randomized population-based trials (BCPP/Ya Tsie, HPTN 071/PopART, SEARCH, ANRS 12249/TasP) conducted in sub-Saharan African(SSA) during expanded antiretroviral treatment (ART) eligibility by World Health Organization guidelines and the UNAIDS 90-90-90 campaign.DiscussionThese three-year studies were conducted in Botswana, Zambia, Uganda, Kenya and South Africa in settings with baseline HIV prevalence from 4% to 30%. Key observations across studies were: (1) Universal testing (implemented via a variety of home and community-based testing approaches) achieved g90% coverage in all studies. (2) When coupled with robust linkage to HIV care, rapid ART start and patient-centred care, UTT achieved among the highest reported population levels of viral suppression in SSA. Significant gains in population-level viral suppression were made in regions with both low and high baseline population viral load; however, viral suppression gains were not uniform across all sub-populations and were lower among youth. (3) UTT resulted innmarked reductions in community HIV incidence when universal testing and robust linkage were present. However, HIV elimination targets were not reached. In BCPP and HPTN 071, annualized HIV incidence was approximately 20% to 30% lower in the intervention (which included universal testing) compared to control arms (no universal testing). In SEARCH (where both arms had universal testing), incidence declined 32% over three years. (4) UTT reduced HIV associated mortality by 23% in the intervention versus control communities in SEARCH, a study in whichnmortality was comprehensively measured.ConclusionsThese trials provide strong evidence that UTT inclusive of universal testing increases population-level viral suppression and decreases HIV incidence and mortality faster than the status quo in SSA and should be adapted at a sub-country level as a public health strategy. However, more is needed, including integration of new prevention interventions into UTT, in order to reach UNAIDS HIV elimination targets.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel.
Michael S. Saag,Rajesh T. Gandhi,Jennifer F Hoy,Raphael J. Landovitz,Melanie A. Thompson,Paul E. Sax,Davey M. Smith,Constance A. Benson,Susan Buchbinder,Carlos del Rio,Joseph J. Eron,Gerd Fätkenheuer,Huldrych F. Günthard,Jean-Michel Molina,Donna M. Jacobsen,Paul A. Volberding +15 more
TL;DR: Advances in HIV prevention and management with antiretroviral drugs continue to improve clinical care and outcomes among individuals at risk for and with HIV.
469
Achieving the 95 95 95 targets for all: A pathway to ending AIDS
Luisa Frescura,Peter Godfrey-Faussett,Ali Feizzadeh A,Wafaa El-Sadr,Omar Syarif,Peter D. Ghys +5 more
TL;DR: The evidence and decisions underpinning the new global targets aim to bridge inequalities in treatment coverage and outcomes and accelerate HIV incidence reductions by focusing on progress in all sub-populations, age groups and geographic settings.
What do the Universal Test and Treat trials tell us about the path to HIV epidemic control
Diane V. Havlir,Shahin Lockman,Shahin Lockman,Helen Ayles,Joseph Larmarange,Gabriel Chamie,Tendani Gaolathe,Tendani Gaolathe,Collins Iwuji,Collins Iwuji,Sarah Fidler,Sarah Fidler,Moses R. Kamya,Sian Floyd,Janet Moore,Richard J. Hayes,Maya L. Petersen,François Dabis +17 more
TL;DR: Universal test and treat (UTT) was evaluated in four randomized population‐based trials conducted in sub‐Saharan Africa during expanded antiretroviral treatment (ART) eligibility by World Health Organization guidelines and the UNAIDS 90‐90‐90 campaign.
Risk of adverse COVID-19 outcomes for people living with HIV: a rapid review and meta-analysis
Maya M. Mellor,Anne C. Bast,Nicholas R Jones,Nia Roberts,José M Ordóñez-Mena,Alastair J M Reith,Christopher C Butler,Philippa C Matthews,Jienchi Dorward +8 more
TL;DR: Evidence is emerging that suggests a moderately increased risk of CO VID-19 mortality amongst PLWH, and tenofovir-disoproxil-fumarate-based regimens were associated with a lower risk of adverse COVID-19 outcomes, although these analyses are susceptible to confounding by comorbidities.
94
Changing Knowledge and Attitudes Towards HIV Treatment-as-Prevention and “Undetectable = Untransmittable”: A Systematic Review
Jacob Bor,Charlie B. Fischer,Mirva Modi,Bruce Richman,Cameron Kinker,Rachel King,Sarah K. Calabrese,Idah Mokhele,Tembeka Sineke,Thembelihle Zuma,Thembelihle Zuma,Sydney Rosen,Sydney Rosen,Till Bärnighausen,Kenneth H. Mayer,Dorina Onoya +15 more
TL;DR: In this paper, the authors systematically reviewed the global literature on knowledge and attitudes related to treatment-as-prevention (TasP) and interventions providing TasP or U'='U' information.
References
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
Myron S. Cohen,Ying Q. Chen,Marybeth McCauley,Theresa Gamble,Mina C. Hosseinipour,Nagalingeswaran Kumarasamy,James Hakim,Johnstone Kumwenda,Beatriz Grinsztejn,José Henrique Pilotto,Sheela Godbole,Sanjay Mehendale,Suwat Chariyalertsak,Breno Santos,Kenneth H. Mayer,Irving F. Hoffman,Susan H. Eshleman,Estelle Piwowar-Manning,Lei Wang,Joseph Makhema,Lisa A. Mills,Guy de Bruyn,Ian Sanne,Joseph J. Eron,Joel E. Gallant,Diane V. Havlir,Susan Swindells,Heather J. Ribaudo,Vanessa Elharrar,David N. Burns,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Myron Essex,Thomas R. Fleming +34 more
TL;DR: In this article, Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples.
Prevention of HIV-1 infection with early antiretroviral therapy
TL;DR: The exciting evidence generated by this paper – that antiretroviral treatment of HIV-1 infection definitively reduces the risk of onward transmission of the virus by 96% – was rightly dubbed Science magazine's ‘Breakthrough of the Year’ in 2011.
5.7K
Initiation of antiretroviral therapy in early asymptomatic HIV infection
Sean Emery,Shweta Sharma,Gerd Fätkenheuer,Josep M. Llibre,Jean-Michel Moli,Paula Munderi,Robin Wood,Karin L. Klingman,Simon Collins,H. Clifford Lane,Andrew N. Phil,James D. Neaton +11 more
TL;DR: The initiation of antiretroviral therapy in HIV-positive adults with a CD4+ count of more than 500 cells per cubic millimeter provided net benefits over starting such therapy in patients after the CD4+, but the risks of unscheduled hospital admissions were similar in the two groups.
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model
TL;DR: A theoretical strategy of universal voluntary HIV testing and immediate treatment with ART, combined with present prevention approaches, could have a major effect on severe generalised HIV/AIDS epidemics.
2.1K
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Christine Danel,Raoul Moh,Delphine Gabillard,Anani Badje,Le Carrou J,Ouassa T,Eric Ouattara,Anzian A,Jean-Baptiste Ntakpe,Albert Minga,Gérard-Menan Kouamé,Bouhoussou F,Emieme A,Abo Kouame,Inwoley A,Toni Td,Ahiboh H,Kabran M,Rabe C,Sidibé B,Nzunetu G,Konan R,Gnokoro J,Gouesse P,Messou E,Dohoun L,Kamagate S,Yao A,Amon S,Kouame Ab,Koua A,Kouamé E,Ndri Y,Ba-Gomis O,Daligou M,Ackoundzé S,Hawerlander D,Ani A,Dembélé F,Koné F,Guéhi C,Kanga C,Koule S,Séri J,Oyebi M,Mbakop N,Makaila O,Babatunde C,Babatounde N,Bleoué G,Tchoutedjem M,Kouadio Ac,Sena G,Yededji Sy,Assi R,Bakayoko A,Mahassadi A,Attia A,Oussou A,Mobio M,Bamba D,Koman M,Horo A,Nina Deschamps,Chenal H,Sassan-Morokro M,Konate S,Aka K,Aoussi E,Journot,Nchot C,Sophie Karcher,Chaix Ml,Christine Rouzioux,Sow Ps,Perronne C,Girard Pm,Menan H,Bissagnene E,Kadio A,Ettiegne-Traore,Moh-Semdé C,Massumbuko Jm,Chêne G,Dosso M,Domoua Sk,N'Dri-Yoman T,Roger Salamon,Serge-Paul Eholié,Xavier Anglaret +89 more
TL;DR: In this African country, immediate ART and 6 months of IPT independently led to lower rates of severe illness than did deferred ART and no IPT, both overall and among patients with CD4+ counts of at least 500 cells per cubic millimeter.
1.2K
Related Papers (5)
Richard J. Hayes,Deborah Donnell,Sian Floyd,Nomtha Mandla,Justin Bwalya,Kalpana Sabapathy,Blia Yang,Mwelwa Phiri,Ab Schaap,Susan H. Eshleman,Estelle Piwowar-Manning,Barry Kosloff,Anelet James,Timothy Skalland,Ethan Wilson,Lynda Emel,David Macleod,Rory Dunbar,Musonda Simwinga,Nozizwe Makola,Virginia Bond,Graeme Hoddinott,Ayana Moore,Sam Griffith,Nirupama Sista,Sten H. Vermund,Wafaa El-Sadr,David N. Burns,James R Hargreaves,Katharina Hauck,Christophe Fraser,Kwame Shanaube,Peter Bock,Nulda Beyers,Helen Ayles,Sarah Fidler,Hptn (PopART) Study Team +36 more
Myron S. Cohen,Ying Q. Chen,Marybeth McCauley,Theresa Gamble,Mina C. Hosseinipour,Nagalingeswaran Kumarasamy,James Hakim,Johnstone Kumwenda,Beatriz Grinsztejn,José Henrique Pilotto,Sheela Godbole,Sanjay Mehendale,Suwat Chariyalertsak,Breno Santos,Kenneth H. Mayer,Irving F. Hoffman,Susan H. Eshleman,Estelle Piwowar-Manning,Lei Wang,Joseph Makhema,Lisa A. Mills,Guy de Bruyn,Ian Sanne,Joseph J. Eron,Joel E. Gallant,Diane V. Havlir,Susan Swindells,Heather J. Ribaudo,Vanessa Elharrar,David N. Burns,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Myron Essex,Thomas R. Fleming +34 more